Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508311 · ClinicalTrials.gov registry record · Phase 4
Albuterol to Improve Respiratory Strength in SCI
A Phase 4 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02508311: Clinical Trial Phase 4 study, sponsored by VA Office of Research and Development.
NCT02508311 is a Phase 4 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02508311, a Phase 4 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
Spinal cord injury (SCI), especially involving the cervical and upper thoracic segments, can significantly compromise respiratory muscle function. Respiratory complications can ensue, including lung collapse and pneumonia, which are the primary cause for mortality in association with traumatic SCI both during the acute and chronic phases post-injury. Lesions at the level of the cervical or high thoracic spinal cord result in respiratory muscle weakness, which is associated with ineffective cough, mucus retention, and mucus plugging. Despite the fact that pulmonary complications are a major cause of morbidity and mortality in this population, there is a paucity of effective interventions in the SCI population known to improve respiratory muscle strength with pharmacologic interventions receiving little to no attention. The current objective of this study is to determine the effectiveness of 16 weeks of sustained release oral Albuterol to; (1) improve respiratory muscular strength, and (2) improve cough effectiveness.
Interventions
- DRUG Placebo
- DRUG Oral Albuterol Extended Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02508311
The ClinicalTrials.gov registry entry for NCT02508311 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02508311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02508311 about?
NCT02508311 is a clinical study titled "Albuterol to Improve Respiratory Strength in SCI". Spinal cord injury (SCI), especially involving the cervical and upper thoracic segments, can significantly compromise respiratory muscle function. Respiratory complications can ensue, including lung collapse and pneumonia, which are the primary cause for mortality in association with traumatic SCI b...
What is the current status of trial NCT02508311?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2016-06-01. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT02508311?
The interventions under investigation include: Placebo (DRUG), Oral Albuterol Extended Release (DRUG).
Who is sponsoring clinical trial NCT02508311?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.